Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells

Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications

(2015) Mohammad Aslam Khan et al.   Oncotarget

PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors

(2014) Marta Martínez-Díez et al.   BIOCHEMICAL PHARMACOLOGY

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

(2014) A. E. Prota et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Interfacial Microtubule Inhibitors of Marine Origin, PM050489/PM060184, with Potent Antitumor Activity and a Distinct Mechanism

(2013) Benet Pera et al.   ACS Chemical Biology

Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds

(2013) María Jesús Martín et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The possible role of chemotherapy in antiangiogenic drug resistance

(2012) Guido Bocci et al.   MEDICAL HYPOTHESES

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH

Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies

(2008) Kyoko Hida et al.   CANCER SCIENCE